• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗血管内皮生长因子治疗糖尿病性黄斑水肿和新生血管性年龄相关性黄斑变性的护理人员体验调查。

Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.

机构信息

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Ophthalmological Unit, Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

Ophthalmic Res. 2024;67(1):516-527. doi: 10.1159/000540390. Epub 2024 Aug 29.

DOI:10.1159/000540390
PMID:39208778
Abstract

INTRODUCTION

Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) require frequent anti-vascular endothelial growth factor (VEGF) treatment and monitoring visits. We aimed to understand the burden of treatment on caregivers.

METHODS

This multinational, noninterventional study used a cross-sectional survey of adult patients with DME or nAMD treated with anti-VEGF injections in the USA, Canada, France, Italy, Spain, and the UK. The survey assessed caregivers' sociodemographic characteristics, patient relationships, patients' clinical history and treatment experiences, caregivers' experiences, and the Caregiver Reaction Assessment of caregiving burden.

RESULTS

Caregivers for patients with DME (n = 30) and nAMD (n = 95) completed surveys. Mean ± standard deviation (SD) age was 64.0 ± 13.4 years, and most were female (71.2%), white (70.4%), married (66.4%), and from Europe (67.2%). Most were caring for their mother/father or partner/spouse (85.6%). Mean ± SD length of time as a caregiver was 9.1 ± 10.0 years. Caregivers estimated they provided support for 4.2 ± 2.9 days/week and 6.0 ± 7.1 h/day on average. Nearly half of caregivers (45.6%) reported some impairment in daily activities, and more than two-thirds (70.5%) of working caregivers (n = 44) reported work absenteeism due to anti-VEGF treatment/monitoring appointments. At least one treatment barrier was reported by 66.7% and 50.5% of caregivers of patients with DME and nAMD, respectively, which were related to coronavirus disease 2019- (38.4%), clinic- (18.4%), social-/health- (13.6%), treatment- (10.4%), or financial-related factors (4.8%). Caregiver Reaction Assessment scores indicated mild-to-moderate burden, with higher caregiver schedule disruption scores associated with an increasing number of anti-VEGF treatment/monitoring visits among DME caregivers (r = 0.61).

CONCLUSION

Caregivers devote substantial time to caregiving, leading to schedule disruptions and absenteeism for some working caregivers. Positive and negative impacts on caregiver mental health were reported.

摘要

简介

糖尿病性黄斑水肿(DME)和新生血管性年龄相关性黄斑变性(nAMD)需要频繁进行抗血管内皮生长因子(VEGF)治疗和监测就诊。本研究旨在了解治疗对护理人员的负担。

方法

这是一项多国家、非干预性研究,使用横断面调查评估了美国、加拿大、法国、意大利、西班牙和英国接受抗 VEGF 注射治疗的 DME 或 nAMD 成年患者的护理人员的社会人口学特征、患者关系、患者的临床病史和治疗经历、护理人员的经历以及 caregiver Reaction Assessment 对护理负担的评估。

结果

完成调查的 DME 患者(n=30)和 nAMD 患者(n=95)的护理人员。平均年龄(标准差)为 64.0±13.4 岁,大多数为女性(71.2%)、白人(70.4%)、已婚(66.4%)和来自欧洲(67.2%)。大多数人照顾他们的母亲/父亲或伴侣/配偶(85.6%)。平均(标准差)作为护理人员的时间为 9.1±10.0 年。护理人员估计他们每周平均提供 4.2±2.9 天的支持,每天提供 6.0±7.1 小时。近一半的护理人员(45.6%)报告说他们的日常活动受到了一些影响,超过三分之二(70.5%)的有工作的护理人员(n=44)因抗 VEGF 治疗/监测预约而缺勤。分别有 66.7%和 50.5%的 DME 和 nAMD 患者的护理人员报告了至少一种治疗障碍,这些障碍与 2019 年冠状病毒病(38.4%)、诊所(18.4%)、社会/健康(13.6%)、治疗(10.4%)或财务相关因素(4.8%)有关。护理人员反应评估得分表明存在轻度至中度负担,DME 护理人员的护理人员日程安排中断得分越高,抗 VEGF 治疗/监测就诊次数就越多(r=0.61)。

结论

护理人员投入大量时间进行护理,导致一些有工作的护理人员的日程安排中断和缺勤。报告了对护理人员心理健康的积极和消极影响。

相似文献

1
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子治疗糖尿病性黄斑水肿和新生血管性年龄相关性黄斑变性的护理人员体验调查。
Ophthalmic Res. 2024;67(1):516-527. doi: 10.1159/000540390. Epub 2024 Aug 29.
2
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿的患者体验调查。
Ophthalmic Res. 2024;67(1):311-321. doi: 10.1159/000538975. Epub 2024 Apr 29.
3
Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿抗血管内皮生长因子治疗的患者偏好:一项多国离散选择实验研究
Ophthalmic Res. 2025;68(1):13-22. doi: 10.1159/000541349. Epub 2024 Nov 21.
4
Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis.新生血管性年龄相关性黄斑变性、糖尿病性视网膜病变或糖尿病性黄斑水肿患者的真实世界治疗及持续性:一项德国医保理赔数据分析
Graefes Arch Clin Exp Ophthalmol. 2025 Mar;263(3):713-725. doi: 10.1007/s00417-024-06690-9. Epub 2024 Nov 25.
5
LESS IS MORE: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME.少即是多:通过抗VEGF疗法减少注射次数并优化湿性年龄相关性黄斑变性、糖尿病性视网膜病变和糖尿病性黄斑水肿患者的视力
Retina. 2024 May 1;44(5S):S1-S16. doi: 10.1097/01.iae.0001023024.39060.66.
6
Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.机器学习可预测接受抗血管内皮生长因子治疗及延长治疗方案的新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞相关黄斑水肿患者的抗 VEGF 药物治疗需求。
Ophthalmol Retina. 2021 Jul;5(7):604-624. doi: 10.1016/j.oret.2021.05.002. Epub 2021 May 8.
7
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.法西单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿:从临床前研究到 3 期结果。
Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3437-3451. doi: 10.1007/s00417-024-06531-9. Epub 2024 Jun 7.
8
Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.个体化治疗-延长方案,优化真实世界的视力结局,提高患者的依从性。
BMC Ophthalmol. 2020 Mar 30;20(1):122. doi: 10.1186/s12886-020-01397-x.
9
Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.玻璃体内注射法西单抗治疗新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞的疗效与安全性:一项荟萃分析
Ophthalmologica. 2024;247(5-6):355-372. doi: 10.1159/000541662. Epub 2024 Oct 3.
10
Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿患者玻璃体内抗血管内皮生长因子治疗后需要保持视力以继续驾驶。
Ophthalmol Retina. 2024 Apr;8(4):388-398. doi: 10.1016/j.oret.2023.10.010. Epub 2023 Oct 20.

引用本文的文献

1
Caregiver Burden Among Patients Receiving Anti-VEGF Intravitreal Injections for AMD and DR: A Cross-Sectional Study in Guangzhou.接受抗血管内皮生长因子玻璃体内注射治疗年龄相关性黄斑变性和糖尿病性视网膜病变患者的照顾者负担:广州的一项横断面研究
Clin Ophthalmol. 2025 Aug 30;19:3071-3078. doi: 10.2147/OPTH.S533237. eCollection 2025.
2
Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性管理临床实践指南的系统评价
Eye (Lond). 2025 May 15. doi: 10.1038/s41433-025-03829-8.